Project Grant R43GM133219

This $295,259 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports Pearl Bio, Inc.'s development of programmable nanobodies for multi-functionalized biologics. The project aims to create synthetic nanobodies encoded with multiple non-canonical amino acids to enable precise tuning of therapeutic properties such as half-life, tumor detection, and cytotoxic payload conjugation. Key...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $303,024 to Biocognon LLC to develop an innovative combinatorial nanobody discovery platform for targeting G protein-coupled receptors (GPCRs). The key objectives of this 1-year project are: 1) Develop a robust assembly system to facilitate efficient construction of GPCR/nanobody libraries, 2) Build a synthetic nanobody...

This Project Grant award from the National Cancer Institute (CFDA Program 93.395 - Cancer Treatment Research) provides $169,329.00 to Wake Forest University Health Sciences to develop and characterize a transgenic mouse model to study B cell-mediated responses to tumor-associated carbohydrate antigens (TACAs). The study aims to better understand the mechanisms regulating antibody responses to TACAs, which are aberrant glycosylation products expressed on cancer cells but absent on most normal...

This Project Grant award, with a total of $602,881 in funding, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The primary objective is to translate tumor cell-penetrating antibodies into the clinic to effectively combat aggressive human cancers driven by common oncogenic mutations. The award supports research at Duke University aimed at engineering new IgG4 antibodies that incorporate a PIGR-binding peptide to enable transcytosis into...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,192,508 to The Medical University of South Carolina (MUSC) to develop a streamlined antibody capture slide array approach called the "Glycotyper" for directly profiling N-glycans of captured serum glycoproteins. This method combines antibody arrays and imaging mass spectrometry to create a new multiplexed N-glycan analysis technique requiring only a...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...

This STTR Phase I award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Immunoblue, LLC for $399,669 aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM). The key products and services to be delivered are: Generating potent and effective patient-derived GBM-specific T cells using a platform that applies Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) to GBM...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $205,621 to the University of Alabama at Birmingham (UAB) to develop a novel framework for nanobody-based targeted radiotherapeutics. The goal is to generate nanobodies that have reduced kidney retention, which can improve the therapeutic index of targeted radiation therapy for cancer and other diseases. The project will assess the feasibility of grafting complementarity...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $147,656 to The Trustees of Columbia University in the City of New York to conduct research on integrating biomaterials and genomic tools for glycan-based programming of immune cells. The key objectives of this 3.5-year research project are to: 1) advance...

The National Cancer Institute (NCI) awarded a $406,520 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Washington State University to develop novel targeted glycodendrimer nanoplatforms (TGDNs) capable of selectively delivering high payloads of chemotherapeutics to prostate cancer cells. The goal is to improve the efficacy and reduce the side effects of the multi-tyrosine kinase inhibitor cabozantinib (CAB) for the treatment of advanced prostate cancer. The project...